This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Various

Cancer; viral infections

Cell division
cycle 42
(CDC42)

In vitro and cell culture studies identified a selective inhibitor of the GTPase CDC42 that could help treat cancer or viral infections. High throughput screening identified compounds that inhibited CDC42 selectively over four other GTPases. In an ovarian cancer cell line-based migration assay, low micromolar concentrations of the lead inhibitor decreased migration compared with vehicle. In hantavirus-infected cells, incubation with inhibitor 60-75 minutes postinfection decreased viral replication compared with vehicle incubation. Next steps include optimizing the CDC42 inhibitor and testing its effects in cell-based models for disease.

SciBX 6(9); doi:10.1038/scibx.2013.225
Published online March 7, 2013

Screening technology patented; patent application filed covering the CDC42 inhibitors; available for licensing

Hong, L. et al. J. Biol. Chem.; published online Feb. 4, 2013;
doi:10.1074/jbc.M112.435941
Contact: Angela Wandinger-Ness, The University of New Mexico, Albuquerque, N.M.
e-mail:

wness@unm.edu
Contact: Larry A. Sklar, same affiliation as above
e-mail:

lsklar@salud.unm.edu